On February 22, 2024, YS Biopharma Co., Ltd announced the results of its extraordinary general meeting held on February 22, 2024, in Hong Kong. The Company's shareholders voted in favor of each of the following resolutions: Resolution 1: as an ordinary resolution, that the appointment of each of Haitao Zhao, Henry Chen, Pierson Yue Pan, Yuntao Cui, Jin Wang, Chunyuan (Brenda) Wu as a director of the Company is hereby reaffirmed, ratified and confirmed in all respects, resolution 2 : as an ordinary resolution, that the Company is hereby authorized and directed to conduct an independent investigation of any alleged misconduct and/or illegal activities of the Company caused by or under the control of Mr. Yi Zhang, the former chairperson of the Company's Board of Directors, resolution 3 : as an ordinary resolution, that the Company is hereby authorized and directed to take immediate actions to strengthen the Company's corporate governance and internal control and management as advised by counsel and other professionals, and resolution 4 : as an ordinary resolution, that the Company is hereby authorized and directed to remove Yi Zhang from all positions with the Company and any subsidiaries of the Company, including without limitation as director, officer and/or legal representative. The Company stated that the results of the vote on each of the resolutions submitted for shareholder approval at the EGM were 99,472,858 votes in favor and 6,508,744 votes against and 1,129,039 votes abstained.